Tong Vivien, Raynor David K, Blalock Susan J, Aslani Parisa
Faculty of Pharmacy, The University of Sydney, Sydney, NSW, Australia.
School of Healthcare, University of Leeds, Leeds, UK.
Health Expect. 2016 Jun;19(3):543-56. doi: 10.1111/hex.12215. Epub 2014 Jun 6.
Consumer Medicine Information (CMI) is a brand-specific and standardized source of written medicine information available in Australia for all prescription medicines. Side-effect information is poorly presented in CMI and may not adequately address consumer information needs.
To explore consumer opinions on (i) the presentation of side-effect information in existing Australian CMI leaflets and alternative study-designed CMIs and (ii) side-effect risk information and its impact on treatment decision making.
Fuzzy trace, affect heuristic, frequency hypothesis and cognitive-experiential theories were applied when revising existing CMI side-effects sections. Together with good information design, functional linguistics and medicine information expertise, alternative ramipril and clopidogrel CMI versions were proposed. Focus groups were then conducted to address the study objectives.
Three focus groups (n = 18) were conducted in Sydney, Australia. Mean consumer age was 58 years (range 50-65 years), with equal number of males and females.
All consumers preferred the alternative CMIs developed as part of the study, with unequivocal preference for the side-effects presented in a simple tabular format, as it allowed quick and easy access to information. Consumer misunderstandings reflected literacy and numeracy issues inherent in consumer risk appraisal. Many preferred no numerical information and a large proportion preferred natural frequencies.
One single method of risk presentation in CMI is unable to cater for all consumers. Consumer misunderstandings are indicative of possible health literacy and numeracy factors that influence consumer risk appraisal, which should be explored further.
消费者用药信息(CMI)是澳大利亚所有处方药都可获取的特定品牌且标准化的书面用药信息来源。CMI中副作用信息呈现不佳,可能无法充分满足消费者的信息需求。
探讨消费者对(i)澳大利亚现有CMI传单及其他研究设计的CMI中副作用信息的呈现方式,以及(ii)副作用风险信息及其对治疗决策的影响的看法。
在修订现有CMI副作用部分时应用了模糊痕迹、情感启发式、频率假设和认知经验理论。结合良好的信息设计、功能语言学和用药信息专业知识,提出了雷米普利和氯吡格雷CMI的替代版本。随后进行焦点小组讨论以实现研究目标。
在澳大利亚悉尼进行了三个焦点小组讨论(n = 18)。消费者平均年龄为58岁(范围50 - 65岁),男女数量相等。
所有消费者都更喜欢作为研究一部分开发的替代CMI,明确偏好以简单表格形式呈现的副作用,因为这样能快速方便地获取信息。消费者的误解反映了消费者风险评估中固有的读写和计算问题。许多人更喜欢没有数字信息,很大一部分人更喜欢自然频率。
CMI中单一的风险呈现方法无法满足所有消费者的需求。消费者的误解表明可能存在影响消费者风险评估的健康读写和计算因素,应进一步探讨。